Brief: NurExone Biologic Announces Advancements In Extracellular Vesicles Functionality With Enhanced Potency And Cellular Uptake For Potentially Better Drug Delivery
20/07/2023 14:17
July 20 (Reuters) - Nurexone Biologic Inc NRX.V :
* NUREXONE BIOLOGIC ANNOUNCES ADVANCEMENTS IN EXTRACELLULAR
VESICLES FUNCTIONALITY WITH ENHANCED POTENCY AND CELLULAR UPTAKE
FOR POTENTIALLY BETTER DRUG DELIVERY
* NUREXONE BIOLOGIC: UNIT GOT EXCLUSIVE WORLDWIDE LICENSE
FROM
TECHNION TO DEVELOP & COMMERCIALIZE PRODUCTION PROCESS FOR USE
FOR MORE INDICATIONS
Source text for Eikon: ID:nGNX6NGQPf
Further company coverage: NRX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement